Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. Its lead product candidate is entospletinib (ENTO), an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Market Cap | 89.327 Million | Shares Outstanding | 57.63 Million | Avg 30-day Volume | 252.087 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.57 |
Price to Revenue | 68.3333 | Debt to Equity | 0.0 | EBITDA | -129.268 Million |
Price to Book Value | 0.3698 | Operating Margin | -10585.0123 | Enterprise Value | -157.852 Million |
Current Ratio | 9.194 | EPS Growth | 0.256 | Quick Ratio | 8.961 |
1 Yr BETA | 2.0568 | 52-week High/Low | 5.74 / 1.2 | Profit Margin | -10088.3702 |
Operating Cash Flow Growth | 40.0466 | Altman Z-Score | -1.8688 | Free Cash Flow to Firm | -73.15 Million |
Earnings Report | 2023-08-03 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2023-04-20 | 2 | |
|
0 | 2023-04-10 | 2 | |
AL-WAKEEL YASIR B. CHIEF FINANCIAL OFFICER |
|
355,719 | 2023-02-24 | 3 |
DIMARTINO JORGE CHIEF MEDICAL OFFICER & VP |
|
355,440 | 2023-02-24 | 4 |
DINSMORE CHRISTOPHER CHIEF SCIENTIFIC OFFICER |
|
285,001 | 2023-02-24 | 4 |
BISCHOFBERGER NORBERT W PRESIDENT & CEO |
|
5,443,853 | 2023-02-15 | 1 |
KOSACZ BARBARA COO & GENERAL COUNSEL |
|
939,642 | 2023-02-15 | 2 |
|
34,000 | 2022-06-22 | 1 | |
|
34,000 | 2022-06-22 | 1 | |
|
34,000 | 2022-06-22 | 1 | |
|
28,333 | 2022-06-22 | 1 | |
|
34,000 | 2022-06-22 | 1 | |
|
34,000 | 2022-06-22 | 1 | |
|
34,000 | 2022-06-22 | 1 | |
|
31,083 | 2022-06-22 | 1 | |
|
1,301,537 | 2021-04-16 | 0 | |
|
1,952,364 | 2020-10-14 | 0 | |
|
No longer subject to file | 2020-10-14 | 0 | |
BISCHOFBERGER NORBERT W. & INGER A. REVOCABLE INTER VIVOS TRUST |
|
No longer subject to file | 2020-10-14 | 0 |
|
679,575 | 2020-10-14 | 0 | |
LACY PAUL A PRESIDENT |
|
71,392 | 2007-04-10 | 0 |
AIN MARK S EXECUTIVE CHAIRMAN |
|
254,916 | 2007-04-03 | 0 |
JULIEN MARK V CHIEF FINANCIAL OFFICER |
|
7,875 | 2007-03-23 | 0 |
DEMARTINO JOSEPH SR. VP, N.A. FIELD OPERATIONS |
|
35,519 | 2007-03-22 | 0 |
GEORGE PETER SR. VP, ENGINEERING AND CTO |
|
74,722 | 2007-03-20 | 0 |
KIZIELEWICZ JAMES SR. VP, CORPORATE STRATEGY |
|
38,354 | 2007-03-16 | 0 |
BUSSELL LLOYD B VICE PRESIDENT, MANUFACTURING |
|
20,751 | 2007-02-05 | 0 |
AIN ARON J CHIEF EXECUTIVE OFFICER |
|
371,732 | 2006-04-17 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-04-24 16:22:40 -0400 | 2023-04-20 | A | 68,000 | a | 68,000 | direct | ||||||||||
2023-04-11 16:40:51 -0400 | 2023-04-10 | A | 68,000 | a | 68,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
KRONOS BIO INC KRON | 2023-05-31 22:15:04 UTC | 2.5079 | 2.5521 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 21:45:04 UTC | 2.5079 | 2.5521 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 21:15:03 UTC | 2.5079 | 2.5521 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 20:45:04 UTC | 2.5079 | 2.5521 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 20:15:06 UTC | 2.5065 | 2.5535 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 19:45:04 UTC | 2.5065 | 2.5535 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 19:15:21 UTC | 2.5065 | 2.5535 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 18:45:03 UTC | 2.5065 | 2.5535 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 18:15:04 UTC | 2.5065 | 2.5535 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 17:45:03 UTC | 2.5065 | 2.5535 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 17:15:05 UTC | 2.5065 | 2.5535 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 16:45:04 UTC | 2.5062 | 2.5638 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 16:15:04 UTC | 2.5062 | 2.5638 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 15:45:03 UTC | 2.5062 | 2.5638 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 15:15:04 UTC | 2.5062 | 2.5638 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 14:45:04 UTC | 2.5062 | 2.5638 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 14:15:03 UTC | 2.5062 | 2.5638 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 13:45:04 UTC | 2.4951 | 2.5749 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 13:15:04 UTC | 2.4951 | 2.5749 | 450000 |
KRONOS BIO INC KRON | 2023-05-31 12:45:04 UTC | 2.4951 | 2.5749 | 450000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund | KRON | -1000.0 shares, $-1460.0 | 2023-03-31 | N-PORT |